liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis
Internal Med Ctr Eppendorf, Germany.
Tech Univ Dresden, Germany.
Semmelweis Univ, Hungary.
Gastroenterology, Private Practice, Berlin, Germany.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012, Vol. 155, nr 6, s. 1795-+Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND amp; AIMS: Lymphocytic colitis is a common cause of chronic, nonbloody diarrhea. However, the effects of treatment are unclear and randomized placebo-controlled trials were requested in a Cochrane review. We performed a randomized, placebo-controlled, multicenter study to evaluate budesonide and mesalazine as induction therapy for lymphocytic colitis. METHODS: Patients with active lymphocytic colitis were randomly assigned to groups given budesonide 9 mg once daily (Budenofalk granules), mesalazine 3 g once daily (Salofalk granules), or placebo for 8 weeks in a double-blind, double-dummy design. The primary endpoint was clinical remission, defined as amp;lt;= 21 stools (including amp;lt;= 6 watery stools), in the 7 days before week 8. RESULTS: The final analysis included 57 patients (19 per group). Most patients were female (72%) and the mean age was 59 years. The proportion of patients in clinical remission at week 8 was significantly higher in the budesonide group than in the placebo group (intention-to-treat analysis, 79% vs 42%; P=.01). The difference in proportions of patients in clinical remission at week 8 between the mesalazine (63%) and placebo groups was not significant (P=.09). The proportion of patients with histologic remission at week 8 was significantly higher in the budesonide group (68%) vs the mesalazine (26%; P=.02) or placebo (21%; P=.008) groups. The incidence of adverse events was 47.4% in the budesonide group, 68.4% in the mesalazine group, and 42.1% in the placebo group. CONCLUSIONS: In a randomized multicenter study, we found oral budesonide 9 mg once daily to be effective and safe for induction of clinical and histologic remission in patients with lymphocytic colitis, compared with placebo. Oral mesalazine 3 g once daily was not significantly better than placebo. ClinicalTrials.gov no: NCT01209208.

sted, utgiver, år, opplag, sider
W B SAUNDERS CO-ELSEVIER INC , 2018. Vol. 155, nr 6, s. 1795-+
Emneord [en]
Corticosteroid; 5-Aminosalicylic Acid; Microscopic Colitis; Intraepithelial Lymphocytes
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-153520DOI: 10.1053/j.gastro.2018.08.042ISI: 000451781000033PubMedID: 30195447OAI: oai:DiVA.org:liu-153520DiVA, id: diva2:1274600
Merknad

Funding Agencies|Dr Falk Pharma GmbH, Freiburg, Germany; Dr Falk Pharma GmbH

Tilgjengelig fra: 2019-01-02 Laget: 2019-01-02 Sist oppdatert: 2019-05-01

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Münch, Andreas

Søk i DiVA

Av forfatter/redaktør
Münch, Andreas
Av organisasjonen
I samme tidsskrift
Gastroenterology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 25 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf